Successful treatment of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa after allogeneic hematopoietic stem cell transplantation with colistin and amikacin inhalation therapy.


Journal

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 07 07 2021
revised: 23 08 2021
accepted: 29 08 2021
pubmed: 15 9 2021
medline: 20 11 2021
entrez: 14 9 2021
Statut: ppublish

Résumé

Pseudomonas aeruginosa is a Gram-negative bacillus that often causes severe infections during immunosuppression in patients with hematologic malignancies. P. aeruginosa can easily acquire drug resistance, and often develops into multidrug-resistant P. aeruginosa (MDRP). Although many antibiotics are used in combination to treat MDRP infections, colistin and amikacin are less likely to be transferred to the lungs, and inhalation therapy may be used. Herein, we report a Case of pneumonia caused by MDRP after allogeneic hematopoietic stem cell transplantation (HSCT) treated with inhaled colistin and amikacin. This 61-year-old female patient was diagnosed with myelodysplastic syndromes and underwent allogeneic HSCT from an 8/8 HLA-matched unrelated donor after reduced-intensity conditioning. On the day of the stem cell infusion, the patient's sputum culture was found to be positive for MDRP. The patient subsequently developed bacteremia, pneumonia, and lung abscess caused by MDRP, and we administered multidrug antibiotic therapy including colistin and amikacin inhalation therapy. The patient's blood cultures were subsequently turned negative, and the lung abscess disappeared. To our knowledge, this is the first case of MDRP pneumonia after HSCT in which colistin and amikacin inhalation therapy was effective.

Identifiants

pubmed: 34518095
pii: S1341-321X(21)00241-5
doi: 10.1016/j.jiac.2021.08.023
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Amikacin 84319SGC3C
Colistin Z67X93HJG1

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

91-94

Informations de copyright

Copyright © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Auteurs

Michiaki Sato (M)

Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Akira Honda (A)

Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Hiroaki Maki (H)

Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Kazuhiro Toyama (K)

Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Ryo Yamaguchi (R)

Department of Pharmacy, The University of Tokyo Hospital, Japan.

Mahoko Ikeda (M)

Department of Infection Control and Prevention, Faculty of Medicine, The University of Tokyo, Japan.

Kyoji Moriya (K)

Department of Infection Control and Prevention, Faculty of Medicine, The University of Tokyo, Japan.

Mineo Kurokawa (M)

Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, Tokyo, Japan. Electronic address: kurokawa@m.u-tokyo.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH